P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids by Hashimoto Naoto et al.
P-Glycoprotein in skin contributes to
transdermal absorption of topical
corticosteroids
著者 Hashimoto Naoto, Nakamichi Noritaka, Yamazaki
Erina, Oikawa Masashi, Masuo Yusuke, Schinkel
Alfred H., Kato Yukio
journal or
publication title







- 1 - 
P-Glycoprotein in skin contributes to transdermal absorption of 
topical corticosteroids 
 
Naoto Hashimoto a,b, Noritaka Nakamichi a, Erina Yamazaki a,  
Masashi Oikawa a, Yusuke Masuo a, Alfred H. Schinkel c and Yukio Kato a,* 
 
a Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa 
University, Kanazawa, Japan 
b Drug Development Research Laboratories, Drug Metabolism and Pharmacokinetic Research 
Division, Maruho Company Ltd., Kyoto, Japan 
c The Netherlands Cancer Institute, Division of Molecular Oncology, Amsterdam, The Netherlands 
 
Corresponding author contact information: 
1. Name: Yukio Kato 
2. E-mail address: ykato@p.kanazawa-u.ac.jp 
3. Tel. /fax: +81 76 234 4465  
4. Full post address: 
Institution: Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, 
Kanazawa University 
Address: Kakuma-machi, Kanazawa 920-1192, Japan 
 
E-mail of authors 
Naoto Hashimoto: nhashimoto@stu.kanazawa-u.ac.jp 
Noritaka Nakamichi: nakamiti@p.kanazawa-u.ac.jp 
Erina Yamazaki: pcfsts0@stu.kanazawa-u.ac.jp 
- 2 - 
Masashi Oikawa: t0t0r0@stu.kanazawa-u.ac.jp 
Yusuke Masuo: masuo@p.kanazawa-u.ac.jp 
Alfred Schinkel: a.schinkel@nki.nl 
- 3 - 
Abstract 
ATP binding cassette transporters, P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP), are expressed in skin, but their involvement in transdermal absorption of clinically used 
drugs remains unknown. Here, we examined their role in transdermal absorption of corticosteroids. 
Skin and plasma concentrations of dexamethasone after dermal application were reduced in P-gp and 
BCRP triple-knockout (Mdr1a/1b/Bcrp−/−) mice. The skin concentration in Mdr1a/1b/Bcrp−/− mice 
was reduced in the dermis, but not in the epidermis, indicating that functional expression of these 
transporters in skin is compartmentalized. Involvement of these transporters in dermal transport of 
dexamethasone was also supported by the observation of a higher epidermal concentration in 
Mdr1a/1b/Bcrp−/− than wild-type mice during intravenous infusion. Transdermal absorption after 
dermal application of prednisolone, but not methylprednisolone or ethinyl estradiol, was also lower in 
Mdr1a/1b/Bcrp−/− than in wild-type mice. Transport studies in epithelial cell lines transfected with 
P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally 
transported by BCRP. Thus, our findings suggest that P-gp is involved in transdermal absorption of at 
least some corticosteroids in vivo. P-gp might be available as a target for inhibition in order to deliver 
topically applied drugs and cosmetics in a manner that minimizes systemic exposure. 
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Abbreviations 
P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; SC, stratum corneum; ABC: 
ATP-binding cassette; MDR1, multidrug resistance 1; MDCK II, Madin-Darby canine kidney II; BL, 
basal; AP, apical; ER, efflux ratio; Papp, apparent permeability coefficient; LC/MS/MS, 




- 5 - 
1. Introduction 
Transdermal drug delivery offers several advantages over conventional oral administration or 
injection, including the avoidance of first-pass metabolism, the minimization of pain and the 
possibility of controlling drug release (Prausnitz and Langer, 2008; Schoellhammer et al., 2014). 
However, skin serves as a physical and biological barrier between the body and the environment to 
prevent unregulated water loss from the body and percutaneous absorption of xenobiotics (Proksch et 
al., 2008). The physical barrier is mainly localized in the stratum corneum (SC), which is the 
outermost layer of skin and consists of anucleate corneocytes and intercellular lipids (Madison, 2003). 
Various techniques have been proposed to increase the skin permeability by disrupting the physical 
barrier in the SC in order to promote transdermal drug delivery (Prausnitz and Langer, 2008; 
Schoellhammer et al., 2014). Skin also functions as a biological barrier containing various metabolic 
enzymes and drug transporters that mediate detoxification and efflux of xenobiotics (Baron et al., 
2001; Schiffer et al., 2003; Ahmad and Mukhtar, 2004; Li et al., 2005; Ito et al., 2008; Svensson 2009; 
Heise et al., 2010; Hewitt et al., 2013). Therefore, this barrier could also have an important influence 
on transdermal absorption of therapeutic agents, though the mechanisms involved remain to be fully 
clarified. 
 Among drug transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which 
are encoded by MDR1 (or ABCB1) and ABCG2 genes, respectively, in humans, and belong to the ATP 
binding cassette (ABC) superfamily have been identified in epidermal keratinocytes of both human 
and mouse (Sleeman et al., 2000; Baron et al., 2001; Triel et al., 2004). Skazik et al. (2011) reported 
the expression of P-gp in basal epidermis and skin appendages including blood vessels in human. 
Hashimoto et al. (2013) have also shown that P-gp and BCRP are expressed in the basal layer of 
epidermis in human, and in dermal endothelial cells of both human and mouse. These two ABC 
transporters may play a central role in the transdermal absorption of their typical substrate rhodamine 
123 (2-[6-amino-3-imino-3H-xanthen-9-yl] benzoic acid methyl ester), at least in rodents, since the 
concentrations of rhodamine 123 in the plasma and dermis after dermal application were greatly 
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reduced in mdr1a/1b and bcrp gene knockout (Mdr1a/1b/Bcrp−/−) mice, compared with wild-type 
mice (Hashimoto et al., 2013). Since these transporters have extremely broad substrate specificity, 
P-gp and/or BCRP might contribute to the transdermal absorption of a variety of therapeutic drugs and 
cosmetic components. 
Various therapeutic agents that are topically applied to the skin or dermally administered for 
systemic delivery are known to be substrates of P-gp. These include immunosuppressive drugs, 
antibiotics, antiviral drugs and corticosteroids such as tacrolimus, erythromycin, acyclovir, 
dexamethasone, prednisolone and betamethasone (Ueda et al., 1992; Saeki et al., 1993; Kim et al., 
1999; Yates et al., 2003; Palmberger et al., 2008) for topical application, and opioid analgesics, 
psychotropic drug, beta-blockers and estrogens such as fentanyl, buprenorphine, methylphenidate, 
bisoprolol and estradiol (Dagenais et al., 2004; Suzuki et al., 2007; Kim and Benet, 2004; Tahara et al., 
2008) for transdermal delivery. P-gp mediates active secretion of its substrate drugs in liver and kidney 
(Koziolek et al., 2001; Hoffmaster et al., 2004), and is responsible for active efflux of its substrate 
drugs across brain endothelial cells and small intestinal epithelial cells (Greiner et al., 1999; Sasongko 
et al., 2005). Although information on the pharmacokinetic roles of BCRP is relatively limited, 
permeation of some therapeutic agents across the blood-brain barrier is hindered by BCRP-mediated 
efflux (Agarwal et al., 2011). In the case of skin, however, transdermal permeation of most therapeutic 
agents applied to the dermal surface is believed to occur mainly by passive diffusion, and the 
contribution of xenobiotic transporters to overall dermal disposition is mostly unknown and believed 
to be minor (Mitragotri et al., 2011). In addition, ABC transporters other than P-gp or BCRP are also 
expressed in the skin (Schiffer et al., 2003; Li et al., 2005; Markova et al., 2009; Heise et al., 2010; 
Kudo et al., 2016), and exhibit wide range of substrate specificity, so that it is difficult to estimate the 
contribution ratio of each transporter to overall dermal drug transport. Thus, it is challenging to 
demonstrate the involvement of these two ABC transporters in transdermal absorption of therapeutic 
agents in vivo. 
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The purpose of the present study is to clarify the role of P-gp and BCRP in transdermal absorption 
of therapeutic agents. Since P-gp and BCRP accept therapeutic agents with a variety of molecular 
sizes as substrates, and passive diffusion of solutes through the skin is hindered by larger molecular 
size, we focused on corticosteroids as transdermally administered P-gp substrate drugs with relatively 
large molecular weight in the present study. To examine the involvement of P-gp and/or BCRP in 
dermal absorption, dexamethasone and other corticosteroids were transdermally administered, and 
their concentration profiles in plasma and skin were compared in wild-type and Mdr1a/1b/Bcrp−/− 
mice. We also conducted a transcellular transport study in epithelial cell lines stably transfected with 
genes encoding P-gp and BCRP to confirm transporter-mediated permeation of those drugs. 
 
2. Materials and methods 
2.1 Materials 
Dexamethasone was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
Prednisolone, ethinyl estradiol and elacridar were obtained from Sigma Chemical Co. Ltd. (St. Louis, 
MO). Itraconazole, Ko143 and methylprednisolone were obtained from LKT Laboratories, Inc. (St. 
Paul, MN). Prednisone was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). All other chemicals 
were commercial products of analytical grade. 
 
2.2 Animals 
 Seven- to nine-week-old male FVB (wild-type) mice and Mdr1a/1b/Bcrp-/- mice were purchased 
from CLEA Japan Inc. (Tokyo, Japan) and Taconic Biosciences, Inc. (Hudson, NY), respectively. The 
mice were kept in a temperature- and light-controlled environment with standard food and tap water 
provided ad libitum. Animal experiments were performed in accordance with the Guidelines for the 
Care and Use of Laboratory Animals in Kanazawa University. At 72 h before transdermal absorption 
experiments, mice were anesthetized with a subcutaneous injection of sodium pentobarbital, and the 
fur over the abdominal skin was removed using an electric hair clipper and depilatory cream. The 
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chemical components of the cream are thioglycolic acid, cetearyl alcohol, polyoxyethylene lauryl ether, 
polyoxyethylene cetyl ether, butylene glycol, ethanol, squalene, paraffin, sodium guaiazulene 
sulfonate, calcium hydroxide and sodium hydroxide. There is no report of their interaction with P-gp 
or BCRP. 
 
2.3 Transdermal absorption study 
Experiments were performed as previously reported with minor modifications (Hashimoto et al., 
2013). Briefly, the test drug was dissolved in dimethyl sulfoxide (dexamethasone, prednisolone and 
methylprednisolone: 50 mg/mL, ethinyl estradiol: 10 mg/mL), and the drug solution (30 µL) was 
applied to a patch (9 mm diameter, Torii Pharmaceutical Co. Ltd., Tokyo, Japan). Under ether 
anesthesia, the abdominal skin was stripped with vinyl tape (Nichiban Co. Ltd., Tokyo, Japan), and 
two patches were applied to abdominal sites. Thus, the dose of dexamethasone, prednisolone and 
methylprednisolone was 2.4 mg/cm2, and that of ethinyl estradiol was 0.47 mg/cm2. At various 
intervals after dermal application of drug, blood was collected from the tail vein and centrifuged to 
obtain plasma. After the last blood sampling, mice were sacrificed under ether anesthesia, and the 
abdominal skin at the location of the patch and brain were collected. In some experiments, the skin 
was divided into epidermis and dermis as described previously (Surber et al., 1990). Briefly, the skin 
was wrapped in aluminum foil, put between two glass plates and warmed at 55 oC for 1 min, and then 
the epidermis was stripped off with the tip of an injection syringe (18G, Terumo, Tokyo, Japan). 
 
2.4 Intravenous infusion study 
Dexamethasone dissolved in saline (50 µg/mL) was injected into the jugular vein at a rate of 
100 ng/min. This dose was set to reach the plasma concentration comparable with that observed after 
the topical administration. At various intervals during intravenous infusion, blood was collected from 
the tail vein and centrifuged to obtain plasma. At 6 h, several tissues including skin, ear, foot and brain 
were also excised. The distribution of dexamethasone was represented as the tissue-to-plasma 
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concentration ratio (μL/mg tissue), which was calculated by dividing the distributed amount of 
dexamethasone in the tissues (ng/mg tissue) by the plasma concentration at 6 h (ng/mL). Abdominal 
skin tissues were divided into epidermis and dermis, and the epidermis-to-dermis concentration ratio 
was also calculated. 
 
2.5 Transport studies in LLC-MDR1 and MDCKII/BCRP/PDZK1 cells 
LLC-PK1 cells stably expressing MDR1 (LLC-MDR1 cells) were previously constructed (Schinkel 
et al., 1995). MDCKII cells stably expressing both BCRP and PDZK1 (MDCKII/BCRP/PDZK1 cells) 
were also previously constructed (Shimizu et al., 2011). Transcellular transport studies were 
performed as previously described with minor modifications (Schinkel et al., 1995; Shimizu et al., 
2011). Briefly, cells were seeded in Transwell polycarbonate inserts (3 mm pore size, 12 mm 
diameter; Corning Life Sciences, Edison, NJ) at a density of 3×105 cells/well. After 3 days of culture, 
the cell monolayers were washed with transport buffer (Hanks’ balanced salt solution, pH 7.4). Drugs 
were dissolved in the same buffer (10 µmol/L), with or without inhibitors, and the solution was added 
to the basal (BL) or apical (AP) chamber. At the designated times, a 100 µL aliquot was collected 
from the opposite side and replaced with an equal volume of fresh buffer. The efflux ratio (ER) of a 
drug was calculated as the ratio of the apparent permeability coefficient (Papp) in the BL-to-AP 
direction to that in the AP-to-BL direction, where Papp was calculated as the slope of the regression 
line in the transport time profile of the drug divided by the initial drug concentration in the donor 
chamber and the cell monolayer surface area (1.1 cm2).  
 
2.6 Measurement of drug concentration 
For the analysis of dexamethasone, prednisolone and methylprednisolone, the plasma and receptor 
samples were mixed with an equal volume of acetonitrile and 3 volumes (v/v) of the internal standard 
(500 ng/mL prednisone) dissolved in acetonitrile. The tissue samples were homogenized in 
10 volumes (w/v) of acetonitrile containing internal standard using Shake Master NEO (Bio Medical 
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Science, Tokyo, Japan). After centrifugation, the supernatant was mixed with an equal volume of 
10 mmol/L ammonium formate. The supernatant was subjected to high-performance liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) with a reverse-phase column (Capcell pak 
MGII C18, 2.1 mm × 50 mm, particle size of 5 μm; Shiseido, Tokyo, Japan). The column was eluted 
at 0.25 mL/min with a mixture of 10 mmol/L ammonium formate and acetonitrile (2:3, v/v) at 40°C. 
The LC/MS/MS system was operated in the electrospray ionization (ESI)-positive mode. The 
mass-to-charge ratios (m/z) were 393.3 and 373.2 for dexamethasone, 361.2 and 147.2 for 
prednisolone, 375.2 and 357.3 for methylprednisolone, and 359.2 and 341.2 for prednisone. For the 
analysis of ethinyl estradiol, the samples were prepared as described above using dexamethasone as an 
internal standard. The supernatant was analyzed in the ESI-negative mode and eluted with a mixture of 
water and acetonitrile (3:2, v/v). The m/z ratios were 295.1 and 144.8 for ethinyl estradiol, and 391.1 
and 361.3 for dexamethasone.  
 
2.7 Determination of mRNA by real-time polymerase chain reaction 
Total RNA was extracted from the skin of a mouse (male, 7 weeks), and complementary DNA was 
synthesized using oligo (dT)12–18 primer, deoxynucleotide triphosphate mix, reverse transcriptase 
buffer, and MultiScribeTM Reverse Transcriptase (Applied Biosystems, Foster City, California). 
Quantification of mRNAs coding xenobiotic transporters was performed in a mixture of cDNA aliquot, 
forward and reverse primers, and THUNDERBIRD SYBR qPCR Mix using an Mx3005P (Agilent 
Technologies, Santa Clara, California). The sequences of forward and reverse primers and the sizes of 
amplicons are shown in Table S1 in Supplementary Material. The polymerase chain reaction 
conditions were initiated by template denaturation at 95°C for 15 min, followed by 40 cycles of 10 s of 
denaturation at 95°C, 30 s of combined primer annealing/extension at 60°C. The expression levels of 
mRNA were normalized to an endogenous control, acidic ribosomal phosphoprotein P0 (36B4). 
 
2.8 Statistical analysis 
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The statistical significance of differences was determined by means of Student’s t-test with p < 0.05 
as the criterion of significance. 
 
3. Results 
3.1. Transdermal absorption of dexamethasone 
P-gp and BCRP are functionally expressed in skin (Hashimoto et al., 2013), but so far there is no 
evidence that these ABC transporters are involved in the transdermal absorption of topical drugs used 
to treat dermatological diseases. In the present study, we first examined the effect of gene deletion on 
the transdermal absorption of the topical steroidal anti-inflammatory drug dexamethasone (Fig. 1). The 
plasma concentration of dexamethasone after dermal administration in Mdr1a/1b/Bcrp−/− mice was 
significantly lower than that in wild-type mice at all time points examined (Fig. 1A). At 6 h after 
dermal administration, the concentration of dexamethasone in the skin at the location of the patch in 
Mdr1a/1b/Bcrp−/− mice was also significantly lower than that in wild-type mice (Fig. 1B). Since skin 
has a multilayer structure, we determined the concentrations of dexamethasone in epidermis and 
dermis separately at 6 h after transdermal administration. The concentration of dexamethasone in 
epidermis was similar in wild-type and Mdr1a/1b/Bcrp−/− mice, whereas that in dermis of 
Mdr1a/1b/Bcrp−/− mice was lower than that in wild-type mice (Fig. 1C). However, quantitative 
discussion should be carefully performed because the difference in dexamethasone concentration in 
dermis between wild-type and Mdr1a/1b/Bcrp-/- mice (Fig. 1C) was not so remarkable, compared with 
that in whole skin (Fig. 1B). This was at least partially due to the loss of dexamethasone during the 
heat separation, because the recovery of dexamethasone during the separation was estimated to be 74 
and 81% in wild-type and Mdr1a/1b/Bcrp-/- mice, respectively. As a control study, the distribution of 
dexamethasone was also examined in the brain, where these transporters act as a barrier against entry 
of their substrates from the systemic circulation. The brain concentration of dexamethasone in 
Mdr1a/1b/Bcrp−/− mice was much higher than that in wild-type mice (Fig. 1D), confirming that P-gp 
and/or BCRP-mediated efflux of dexamethasone from the brain occurs in vivo. This is consistent with 
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previous reports showing that P-gp limits the entry of dexamethasone into the brain (Schinkel et al., 
1995; Uchida et al., 2011), although the involvement of BCRP has not been reported. 
 
3.2. Gene deletion of P-gp and BCRP minimally affects systemic elimination, but increases 
distribution of dexamethasone to epidermis 
Although the difference in plasma concentration profile of dexamethasone after dermal application 
between wild-type and Mdr1a/1b/Bcrp−/− mice (Fig. 1A) can be explained by a difference in 
transdermal absorption, it is also possible that there might be a difference in systemic elimination. To 
examine this possibility, the plasma concentration profile of dexamethasone was measured during 
intravenous infusion of dexamethasone. The plasma concentration profile of dexamethasone during 
intravenous infusion was almost the same in the two strains (Fig. 2A), indicating that any difference in 
systemic elimination is minimal. The tissue concentrations were also measured at 6 h after the start of 
infusion. The tissue-to-plasma concentration ratio in the brain of Mdr1a/1b/Bcrp−/− mice was much 
higher than that in wild-type mice (Fig. 2D), whereas that in side abdominal skin showed no 
significant difference between wild-type and Mdr1a/1b/Bcrp−/− mice (Fig. 2B). The tissue-to-plasma 
concentration ratio in the skin samples from other sites (abdomen, back, glabella and neck) as well as 
ear, forefoot and hind foot was also similar between the two strains (data not shown). On the other 
hand, when we separately evaluated dexamethasone concentrations in the epidermis and dermis of side 
abdominal skin, a significantly higher concentration was observed in epidermis of Mdr1a/1b/Bcrp−/− 
mice, compared with that in wild-type mice (Fig. 2C). The epidermis-to-dermis concentration ratio of 
dexamethasone in Mdr1a/1b/Bcrp−/− mice (1.52 ± 0.07) was also higher than that in wild-type mice 
(0.948 ± 0.098). 
 
3.3. Transport of dexamethasone by P-gp, but not BCRP 
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To determine whether dexamethasone is a substrate of P-gp and/or BCRP, we examined the 
transcellular transport of dexamethasone across LLC-MDR1 and MDCKII/PDZK1/BCRP cell 
monolayers. The permeation of dexamethasone in the BL-to-AP direction across LLC-MDR1 cells 
was higher than that in the AP-to-BL direction (Fig. 3A). This transcellular transport in the AP-to-BL 
direction was increased in the presence of the P-gp inhibitor itraconazole (Fig. 3A). The ER value in 
the presence of itraconazole was lower than that in its absence, suggesting that dexamethasone is a 
substrate of P-gp. The permeation of dexamethasone in the BL-to-AP direction across 
MDCKII/PDZK1/BCRP cells was similar to that in the AP-to-BL direction, and the BCRP inhibitor 
Ko143 had no effect on the transcellular transport (Fig. 3B). 
 
3.4. Transdermal absorption and P-gp-mediated transport of other topical steroids 
To examine the involvement of P-gp in the transdermal absorption of other topical drugs, we further 
examined the transdermal absorption of prednisolone, methylprednisolone and ethinyl estradiol in 
wild-type and Mdr1a/1b/Bcrp−/− mice (Fig. 4). The plasma concentration of prednisolone in 
Mdr1a/1b/Bcrp−/− mice was lower than that in wild-type mice, showing significant differences at 0.5, 
4 and 6 h after dermal administration (Fig. 4A). The skin concentration of prednisolone in 
Mdr1a/1b/Bcrp−/− mice was also lower, but the brain concentration in Mdr1a/1b/Bcrp−/− mice was 
higher than that in wild-type mice (Fig. 4B, 4C), as in the case of dexamethasone (Fig. 1B, 1D). This 
is consistent with the previous report that P-gp decreases the brain distribution of prednisolone 
(Karssen et al., 2002). On the other hand, the plasma and skin concentrations of methylprednisolone in 
Mdr1a/1b/Bcrp−/− mice were not so much different from those in wild-type mice after transdermal 
administration (Fig. 4D and 4E), whereas the brain concentration in Mdr1a/1b/Bcrp−/− mice was much 
higher than that in wild-type mice (Fig. 4F). The plasma, skin and brain concentrations of ethinyl 
estradiol after transdermal administration were similar in wild-type and Mdr1a/1b/Bcrp−/− mice (Fig. 
4G-I).  
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To directly confirm transport by the ABC transporters, we examined the transcellular transport of 
these three steroids across LLC-MDR1 and MDCKII/PDZK1/BCRP cells monolayers. The 
transcellular transport of prednisolone and methylprednisolone in the BL-to-AP direction across 
LLC-MDR1 cells was higher than that in the AP-to-BL direction (Fig. 3C and 3E). Effect of more 
potent P-gp inhibitor elacridar on the directional transport was also examined to clearly evaluate 
whether P-gp transports these steroid or not. In the presence of elacridar, AP-to-BL transport of these 
drugs was increased, whereas BL-to-AP transport was decreased (Fig. 3C and 3E). The ER values of 
prednisolone and methylprednisolone in the presence of elacridar were lower than those in its absence.  
On the other hand, ethyinyl estradiol exhibited no directional transport across LLC-MDR1 cells (Fig. 
3G). Transport of prednisolone and methylprednisolone in the BL-to-AP direction across 
MDCKII/PDZK1/BCRP cells was slightly higher than that in the AP-to-BL direction, but Ko143 did 
not influence the transcellular transport (Fig. 3D and 3F). Ethyinyl estradiol did not exhibit directional 
transport across MDCKII/PDZK1/BCRP cells, and Ko143 had no effect (Fig. 3H).  
 
3.5. Gene deletion of P-gp and BCRP minimally affects gene expression of other ABC xenobiotic 
transporters in skin 
To examine possible secondary effects of gene deletion on the expression of other ABC 
xenobiotic transporters in Mdr1a/1b/Bcrp−/− mice, the mRNA levels for multidrug resistance 
associated protein (MRP) 1 to MRP5 were measured in the skin of wild-type and 
Mdr1a/1b/Bcrp−/−mice. Gene expression of MRP1, 3, 4 and 5 was similar in wild-type and 
Mdr1a/1b/Bcrp−/− mice, while expression of MRP2 was not detected in either of the strains (Fig. 5). 
Thus, gene expression of these MRPs seems not to be affected by knockout of mdr1a/1b/bcrp genes. 
 
4. Discussion 
Transdermal absorption of therapeutic agents, including topical corticosteroids, has been considered 
to be mediated principally by passive diffusion (Mitragotri et al., 2011). On the other hand, xenobiotic 
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transporters including P-gp and BCRP have been identified in both mouse and human skin (Sleeman et 
al., 2000; Baron et al., 2001; Triel et al, 2004; Skazik et al., 2011; Hashimoto et al., 2013), although 
their roles in the skin are largely unknown. Our present results provide the first evidence that P-gp 
contributes to transdermal absorption of topical corticosteroids, including dexamethasone. (i) First, the 
plasma and skin concentrations after topical application of dexamethasone in Mdr1a/1b/Bcrp−/− mice 
were lower than those in wild-type mice (Fig. 1A, 1B). (ii) The plasma concentration profile of 
dexamethasone after intravenous administration was similar in the two strains (Fig. 2A), indicating 
that the difference in plasma concentration profile after dermal application (Fig. 1A) cannot be 
explained by a difference in systemic elimination, and therefore could be due to a difference in 
transdermal absorption. (iii) Directional transport of dexamethasone in the BL-to-AP direction was 
observed in LLC-MDR1cells (Fig. 3A), but not in MDCKII/PDZK1/BCRP cells (Fig. 3B), and this 
transport was reduced in the presence of the P-gp inhibitor itraconazole (Fig. 3A). (iv) When skin was 
separated into epidermis and dermis, the concentration of dexamethasone was reduced only in dermis 
in Mdr1a/1b/Bcrp−/− mice (Fig. 1C), and this is consistent with the finding reported for the typical 
P-gp substrate rhodamine 123 (Hashimoto et al., 2013). (v) Plasma and skin concentrations after 
topical application of another P-gp substrate corticosteroid, prednisolone, were also lower in 
Mdr1a/1b/Bcrp−/− mice than in wild-type mice (Fig. 4A, 4B), suggesting that P-gp-mediated 
transdermal absorption of topical drugs may not be specific to dexamethasone. However, the reduction 
in the transdermal absorption in Mdr1a/1b/Bcrp−/− mice was only partial in the cases of 
dexamethasone and prednisolone (Fig. 1A, 4A), suggesting possible involvement of other 
mechanism(s) than P-gp in their absorption. In the transdermal administration of steroids, SC was 
removed by tape stripping because the loss of SC is often observed in the skin of atopic dermatitis. In 
addition, DMSO was used as a vehicle for steroids topically applied using the patch to control the dose 
and applied area as previously reported (Ito et al., 2008). As DMSO is known to extract lipid in skin, 
possible morphological change in the skin cannot be excluded during the transdermal administration. 
Nevertheless, the present findings provide the first evidence that P-gp expressed in the skin plays a 
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role in transdermal absorption of topically applied corticosteroids. 
Among topical therapeutic drugs, corticosteroids are widely used for various skin diseases, and 
especially are used as first-line drugs for atopic dermatitis (Ference and Last, 2009; Ring et al., 2012). 
However, the long-term use of topical corticosteroid may cause severe systemic adverse effects, 
including adrenal suppression, hyperglycemia and glaucoma, as well as local adverse effects including 
skin atrophy and acne (Hengge et al., 2006). These adverse effects of topical corticoids limit their 
practical use and may influence patient compliance with the treatment. Therefore, various techniques 
and formulations have been proposed (Korting et al., 2002; Sul et al., 2013; Siddique et al., 2015) to 
reduce absorption of topical corticosteroids into the systemic circulation and/or improve their retention 
in the skin. Our present results suggest that inhibition of P-gp may decrease the distribution of topical 
corticosteroid to the systemic circulation after dermal application, and thus may improve retention in 
skin. This hypothesis is supported by the present findings that the concentrations of dexamethasone in 
plasma and dermis after dermal application were decreased in Mdr1a/1b/Bcrp−/− mice, but the 
concentration in the epidermis was similar in wild-type and Mdr1a/1b/Bcrp−/− mice (Fig. 1). Thus, 
P-gp inhibitors may be useful to minimize the systemic side effects of topical corticosteroids without 
reducing their efficacy in skin, provided that the inflammatory target is localized within the epidermis. 
P-gp inhibitors are present in topical therapeutic agents for skin diseases, such as ketoconazole, 
erythromycin and tacrolimus, and excipients for topical formulations, such as polyethylene glycol-300 
and pluronic P85 (Batrakova et al., 2001; Ekins et al., 2002; Hugger et al., 2002; Kishimoto et al., 
2014). Therefore, the modulation of P-gp activity by the coadministration of P-gp inhibitor may be a 
feasible technique to control the transdermal absorption of topical corticosteroids. Further work will be 
needed to test this idea. 
In the present study, the concentrations of methylprednisolone and ethinyl estradiol in both skin and 
plasma of Mdr1a/1b/Bcrp−/− mice were similar to those in wild-type mice in vivo (Figs. 1 and 3), 
although methylprednisolone was found to be a P-gp substrate in LLC-MDR1 cells in vitro (Fig. 3E). 
Thus, P-gp substrates identified in in vitro transport studies may not necessarily be efficient substrates 
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of P-gp in the skin in vivo. Indeed, in preliminary studies, we also examined transdermal absorption of 
other P-gp substrate drugs, including cyclosporin A, itraconazole and ketoconazole, but observed only 
minimal differences between wild-type and Mdr1a/1b/Bcrp−/− mice (data not shown). The lack of 
influence of P-gp gene knockout on transdermal absorption of methylprednisolone could be explained 
by high skin permeability of methylprednisolone compared to dexamethasone and prednisolone, 
resulting in a lower contribution of P-gp to overall transdermal transport. Indeed, the concentration of 
methylprednisolone in skin after dermal application (~800 ng/mg tissue) was much higher than that of 
dexamethasone and prednisolone (100~200 ng/mg tissue), even though the same dose of each drug 
was topically applied (Figs. 1B, 4B and 4E). Thus, P-gp may significantly influence the transdermal 
absorption of only topical therapeutic drugs whose permeability is relatively low. On the other hand, 
P-gp may also contribute to the skin distribution of other therapeutic drugs after systemic 
administration. For example, the SC-to-serum concentration ratio of fluconazole after oral 
administration in humans was reported to be higher than that of ketoconazole (Harris et al., 1983; 
Faergemann and Laufen, 1993). The brain distribution of ketoconazole in P-gp knockout mice after 
intraperitoneal injection was higher than that in wild-type mice, but that of fluconazole after oral 
administration were similar in the two strains (Yasuda et al., 2002; von Moltke et al., 2004), 
suggesting that ketoconazole, but not fluconazole is a substrate of P-gp in vivo. Since P-gp regulates 
transport from epidermis to dermis, and that from dermis to circulation, the higher SC-to-serum 
concentration ratio of fluconazole may be explained in terms of lower transport efficiency by P-gp, 
leading to lower transport from epidermis to the circulation. 
In Mdr1a/1b/Bcrp−/− mice, the concentration of dexamethasone in dermis was reduced after topical 
application (Fig. 1C), whereas that in epidermis was increased after intravenous administration (Fig. 
2C), compared with wild-type mice. This observation can be quantitatively explained by a 
two-compartment model which was previously proposed (Hashimoto et al., 2013) and separated skin 
into viable epidermis and dermis (Fig. S1, see Supplementary Material for details).  
In the present study, we could not evaluate the contribution of BCRP to the transdermal absorption 
- 18 - 
of topical corticosteroids because the steroids examined in the present study were found not to be 
BCRP substrates (Fig. 3). However, we have previously reported that the concentrations of rhodamine 
123 in skin and plasma of Mdr1a/1b/Bcrp−/− mice tended to be lower than those in P-gp knockout 
(Mdr1a/1b−/−) mice (Hashimoto et al., 2013), suggesting that BCRP may also be involved in 
transdermal absorption. Other xenobiotic transporters such as MRPs, carnitine/organic cation 
transporter 1 (OCTN1) and oligopeptide transporter 2 (PEPT2) were also reported to be functionally 
expressed in epidermis (Li et al., 2005; Markova et al., 2009; Heise et al., 2010; Kudo et al., 2016). Li 
et al. (2005) have reported that MRP1 contributes to the efflux of two substrates, fluo3 and 
grepafloxacin, from skin. Heise et al. (2010) also reported that MRPs are involved in efflux of steroid 
hormones and contact allergens such as eugenol in human keratinocytes. Markova et al. (2009) found 
that OCTN1 contributes to the uptake of its substrate antioxidant L-ergothioneine in keratinocytes. 
These reports, however, did not examine transdermal absorption after topical application of transporter 
substrates. On the other hand, Kudo et al. (2016) recently reported that PEPT2 contributes to the skin 
penetration of dipeptide glycylsarcosine in the absorptive direction. Thus, various transporters may be 
involved in the transport of their substrates in both influx and efflux directions in the skin. 
Furthermore, since these transporters are expressed in epidermis (Markova et al., 2009; Heise et al., 
2010; Kudo et al., 2016), drug transporters may cooperatively play a role in controlling the dermal 
disposition of drugs and cosmetics, implying that these transporters may be available as targets to 
control exposure to topically applied compounds in various drug delivery systems. 
 
5. Conclusions 
Our present findings indicate for the first time that P-gp contributes to the transdermal absorption of 
topical corticosteroids, including dexamethasone. Modulation of P-gp activity may be a useful 
approach to control the retention of P-gp substrates in the dermal epidermis and to decrease their 
systemic absorption. The present findings thus open up a new strategy for transdermal drug delivery, 
targeting dermal transporters. 
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Legends for figures 
Fig. 1. Transdermal absorption of dexamethasone in mice after topical application to tape-stripped 
skin.  
Dexamethasone dissolved in DMSO (30 µL of 50 mg/mL) was applied to two patches for topical 
administration, and the patches were applied to tape-stripped abdominal skin. The concentration of 
dexamethasone in plasma (A) was measured in wild-type (open circles) and Mdr1a/1b/Bcrp−/− (closed 
circles) mice. Concentrations in skin (B), epidermis (C), dermis (C) and brain (D) were also measured 
at 6 h after the start of topical application in wild-type (open columns) and Mdr1a/1b/Bcrp−/− (closed 
columns) mice. Data are expressed as the mean ± S.E.M. (n = 9 and 4 in plasma and tissue samples, 
respectively). *Significantly different from wild-type mice (p < 0.05). 
 
Fig. 2. Plasma concentration and tissue distribution of dexamethasone in wild-type and 
Mdr1a/1b/Bcrp−/− mice during intravenous infusion.  
Dexamethasone was intravenously infused at a rate of 100 ng/min. The concentration of 
dexamethasone in plasma (A) was measured in wild-type (open circles) and Mdr1a/1b/Bcrp−/− (closed 
circles) mice. Tissue-to-plasma concentration ratios in side abdominal skin and brain (B and D, 
respectively), and concentration in epidermis and dermis of the side abdominal skin (C) were also 
measured at 6 h after the start of infusion in wild-type (open columns) and Mdr1a/1b/Bcrp−/− (closed 
columns) mice. Tissue-to-plasma concentration ratios were calculated by dividing the distributed 
amount in the tissue by the plasma concentration at 6 h (B and D). Data are expressed as the 
mean ± S.E.M (n=4-5). *Significantly different from the wild-type mice (p < 0.05). 
 
Fig. 3. Transcellular transport of dexamethasone (A, B), prednisolone (C, D), methylprednisolone (E, 
F) and ethinyl estradiol (G, H) by P-gp and BCRP.  
Transport of dexamethasone (10 µmol/L) in the AP-to-BL (squares) and BL-to-AP (circles) directions 
was measured across LLC-MDR1 cells (A, C, E, G) and MDCKII/PDZK1/BCRP cells (B, D, F, H). 
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Transport was examined in the presence (closed symbols) or absence (open symbols) of the MDR1 
inhibitor itraconazole (25 µmol/L, panel A) or elacridar (5 μmol/L, panels C, E, G) in LLC-MDR1 
cells and the BCRP inhibitor Ko143 (1 µmol/L) in MDCKII/PDZK1/BCRP cells. Each value 
represents the mean ± S.E.M. (n = 3).  
 
Fig. 4. Transdermal absorption of prednisolone, methylprednisolone and ethinyl estradiol in mice after 
topical application to tape-stripped skin. 
Prednisolone (50 mg/mL), methylprednisolone (50 mg/mL) and ethinyl estradiol (10 mg/mL) 
dissolved in DMSO (30 µL) were each applied to patches for topical administration, and two patches 
were applied to tape-stripped abdominal skin. Plasma concentrations of prednisolone (A), 
methylprednisolone (D) and ethinyl estradiol (G) were measured in wild-type (open circles) and 
Mdr1a/1b/Bcrp−/− (closed circles) mice. Concentrations of prednisolone (B, C), methylprednisolone (E, 
F) and ethinyl estradiol (H, I) in skin (B, E, H) and brain (C, F, I) were also measured at 6 h after the 
topical application in wild-type (open columns) and Mdr1a/1b/Bcrp−/− (closed columns) mice. Data 
are expressed as the mean ± S.E.M. (n = 3-4). *Significantly different from wild-type mice (p < 0.05). 
 
Fig. 5. Gene expression of various ABC transporters in skin of wild-type and Mdr1a/1b/Bcrp−/− mice. 
The mRNA level for each transporter in wild-type (open columns) and Mdr1a/1b/Bcrp−/− (closed 
columns) mice was quantified by RT-PCR and normalized by that of 36Β4. Each point represents the 
mean ± S.E.M. (n = 3). N.D., not detectable. 
 
 
